Skip to content
Citation only via OpenAlex

A Regulatory Pathway for Medicines That Target Aging

G. Alexander Fleming, Jennifer H. Zhao, Thomas C Seoh, Nir Barzilai

Public Policy & Aging Report · 2019 · ▲ 6 citations

Abstract

With the world’s population growing older and the primary causes of death shifting to noncommunicable, chronic diseases, there is a high unmet need for interventions that delay or prevent chronic disease. The emerging science of biological aging (geroscience) has demonstrated the feasibility of slowing biological aging, delaying chronic diseases, and spending more time living free from chronic disease, also known as increasing the “healthspan(definition).” Despite these scientific advances, the Food and Drug Administration (FDA) and other major authorities have not articulated a regulatory pathway for licensing products with age-related claims. Regulation of the development of medicines has traditionally focused on the treatment of specific diseases and functional impairments. The perception is that a gap is expanding between what science may offer as age-related interventions and what drug regulation can provide in response. An approach that is consistent with FDA policy and practice is exemplified by the primary efficacy endpoint and proposed analysis of the Targeting Aging with Metformin (TAME) trial. Efficacy in this trial has been defined by reducing the time to the first occurrence of any one of several chronic diseases. This approach avoids the daunting challenges of defining the aging process and validating measures to assess it. In essence, TAME aims to show a positive effect on the measure of healthspan, which is defined as the period of life or length of time spent in the absence of any major, age-related disease (Barzilai, Crandall, Kritchevsky, & Espeland, 2016; Kaeberlein, 2018). Instead of making aging a disease, the focus is on delaying or preventing chronic diseases in aging. To expedite the translation of emerging science into material gains in public health, innovations are needed in other domains: clinical investigation, health-care economics, and commercialization. Extending healthspan and changing the emphasis from disease management to disease prevention represent two of the most important challenges and opportunities for patients and would-be non-patients, their quality of life, and societal economics in this century.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/ppar/prz018
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Fleming, G.A., Zhao, J.H., Seoh, T.C., &amp; Barzilai, N. (2019). A Regulatory Pathway for Medicines That Target Aging. <em>Public Policy & Aging Report</em>. https://doi.org/10.1093/ppar/prz018
Vancouver
Fleming GA, Zhao JH, Seoh TC, Barzilai N. A Regulatory Pathway for Medicines That Target Aging. Public Policy & Aging Report. 2019. doi:10.1093/ppar/prz018.
BibTeX
@article{g2019ARegul, title = {A Regulatory Pathway for Medicines That Target Aging}, author = {G. Alexander Fleming and Jennifer H. Zhao and Thomas C Seoh and Nir Barzilai}, journal = {Public Policy & Aging Report}, year = {2019}, doi = {10.1093/ppar/prz018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings